New hope for ovarian cancer: could Rina-S outperform standard chemo?
NCT ID NCT07564141
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests a new drug called Rina-S (with or without bevacizumab) against standard platinum-based chemotherapy for people with ovarian cancer that has come back but still responds to platinum treatments. About 688 participants will be randomly assigned to receive either the new drug or standard chemo. The goal is to see if Rina-S can delay cancer growth better than current options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.